<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159573">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01659294</url>
  </required_header>
  <id_info>
    <org_study_id>1-Elliott</org_study_id>
    <nct_id>NCT01659294</nct_id>
  </id_info>
  <brief_title>Diabetes Outcomes and Nurse Case Manager Study</brief_title>
  <acronym>DONCM</acronym>
  <official_title>Impact of Nurse Case Management on Diabetes-related Health Outcomes in a Specialty Care Setting: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BCDiabetes.Ca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BCDiabetes.Ca</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine whether patients with diabetes who are either 1) newly discharged
      from hospital or 2) referred to an endocrinologist for management will have better diabetes
      outcomes when their care is managed primarily by a dedicated case manager (intervention)
      than by an endocrinologist (standard care) after 6 months of treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a randomized-control trial recruiting patients with type 2 diabetes in a
      specialty care setting from two sources:

        1. referred by family physicians with inadequate glycemic control likely requiring
           exogenous insulin therapy

        2. referred by medical staff at Vancouver General Hospital or St. Paul's Hospital during
           in-patient care &amp; about to be discharged (Appendix 1).

      Patients who meet the inclusion criteria will be randomly assigned into either the NCM group
      or SC group. Primary and secondary data, including A1C, fasting glucose, lipid profile,
      eGFR, blood pressure, BMI, self-report measures, adherence to annual eye exam/vaccination,
      emergency visits and hospital stays will be collected at baseline, 3-months (only for NCM
      group), and 6 months.

      Study Population Number of Patients The literature suggests the probability of meeting
      targets on all three outcomes is about 10% in the control group and about 22% in the
      treatment group. In order to detect this increase in probability of success in all three
      groups with an 80% power and a 5% significance level, we require 146 patients per group.
      Since the analysis will include a factor for recruitment location as well as some other
      baseline covariates, we will recruit an additional 9 patients per group to cover lost power
      due to these nuisance parameters in the model. In total we will recruit 310 patients split
      equally between treatment and control.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>A1c</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>achievement of A1c &lt; 7.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>target LDL &lt;2.0 mmol/L (=76 mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>blood pressure</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>&lt; 140/90</description>
  </primary_outcome>
  <primary_outcome>
    <measure>weight</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>achieved weight, change in weight</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life measures</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>changes in quality of life measures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">310</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>nurse case management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nurse case management of diabetic variables</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard diabetologist care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard diabetologist care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Nurse Case Management</intervention_name>
    <arm_group_label>nurse case management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>standard diabetologist care</intervention_name>
    <description>routine care by diabetologist &amp; team</description>
    <arm_group_label>standard diabetologist care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  A1c &gt; 8.0 or

          -  BP &gt; 140/90 or

          -  LDL cholesterol &gt; 2.0 (72 mg/dl)

        Exclusion Criteria:

          -  inability to speak English or to be assisted by somebody fluent in English
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Elliott, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerri Klein, BSN</last_name>
    <phone>6046752491</phone>
    <email>gklein@bcdiabetes.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvonne Lam, BSc</last_name>
    <phone>6046752491</phone>
    <email>moa@bcdiabetes.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bcdiabetes.Ca</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6R 1B6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerri Klein, MSc</last_name>
      <phone>6047243867</phone>
      <email>gklein@bcdiabetes.ca</email>
    </contact>
    <investigator>
      <last_name>Tom Elliott, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ehud Ur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>https://docs.google.com/open?id=0B9471Ysm3fNqLWdjQy1FVkVDelk</url>
    <description>Protocol</description>
  </link>
  <link>
    <url>https://docs.google.com/open?id=0B9471Ysm3fNqZDZOMEFncElHRk0</url>
    <description>Consent form</description>
  </link>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 24, 2012</lastchanged_date>
  <firstreceived_date>August 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>BCDiabetes.Ca</investigator_affiliation>
    <investigator_full_name>Tom Elliott</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>outcomes</keyword>
  <keyword>case management</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
